1 – 57 of 57
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Digital remote assessment of speech acoustics in cognitively unimpaired adults : feasibility, reliability and associations with amyloid pathology
(
- Contribution to journal › Article
-
Mark
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
(
- Contribution to journal › Scientific review
-
Mark
Clinical recognition of frontotemporal dementia with right anterior temporal predominance : A multicenter retrospective cohort study
2024) In Alzheimer's and Dementia(
- Contribution to journal › Article
- 2023
-
Mark
APOE Genotype in the Era of Disease-Modifying Treatment with Monoclonal Antibodies Against Amyloid-β
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline
(
- Contribution to journal › Article
-
Mark
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
(
- Contribution to journal › Article
-
Mark
Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population : The ABIDE project
(
- Contribution to journal › Article
-
Mark
Longitudinal Tau PET Using 18F-Flortaucipir : The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
2023) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 64(2). p.281-286(
- Contribution to journal › Article
-
Mark
Tau pathology as determinant of changes in atrophy and cerebral blood flow : a multi-modal longitudinal imaging study
(
- Contribution to journal › Article
-
Mark
Tau protein spreads through functionally connected neurons in Alzheimer's disease : a combined MEG/PET study
(
- Contribution to journal › Article
-
Mark
A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
(
- Contribution to journal › Article
-
Mark
Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease : a natural language processing study
(
- Contribution to journal › Article
-
Mark
Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia with Lewy Bodies
(
- Contribution to journal › Article
-
Mark
European consensus for the diagnosis of MCI and mild dementia : Preparatory phase
(
- Contribution to journal › Article
- 2022
-
Mark
Does Loss of Integrity of the Cingulum Bundle Link Amyloid-β Accumulation and Neurodegeneration in Alzheimer's Disease?
(
- Contribution to journal › Article
-
Mark
Blood-based biomarkers for Alzheimer's disease : towards clinical implementation
(
- Contribution to journal › Scientific review
-
Mark
Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The natural history of primary progressive aphasia : beyond aphasia
(
- Contribution to journal › Article
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals
(
- Contribution to journal › Article
- 2021
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies
(
- Contribution to journal › Article
-
Mark
Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
-
Mark
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
- 2020
-
Mark
Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article
-
Mark
A clinical-radiological framework of the right temporal variant of frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Comorbid amyloid-β pathology affects clinical and imaging features in VCD
(
- Contribution to journal › Article
-
Mark
Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
(
- Contribution to journal › Article
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Latent atrophy factors related to phenotypical variants of posterior cortical atrophy
(
- Contribution to journal › Article
-
Mark
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
(
- Contribution to journal › Article
-
Mark
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
(
- Contribution to journal › Article
- 2019
-
Mark
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
(
- Contribution to journal › Article
-
Mark
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum
(
- Contribution to journal › Article
-
Mark
Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort : The ABIDE project
2019) In Alzheimer's and Dementia(
- Contribution to journal › Article
-
Mark
Applying the ATN scheme in a memory clinic population : The ABIDE project
(
- Contribution to journal › Article
-
Mark
Amyloid-β load is related to worries, but not to severity of cognitive complaints in individuals with subjective cognitive decline : The science project
(
- Contribution to journal › Article
-
Mark
Amyloid PET and cognitive decline in cognitively normal individuals : the SCIENCe project
(
- Contribution to journal › Article
-
Mark
Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment : the effect of age at onset
(
- Contribution to journal › Article
-
Mark
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE) : a modelling study
(
- Contribution to journal › Article
- 2018
-
Mark
Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia
(
- Contribution to journal › Article
-
Mark
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
(
- Contribution to journal › Article
- 2017
-
Mark
Cerebrovascular and amyloid pathology in predementia stages : The relationship with neurodegeneration and cognitive decline
(
- Contribution to journal › Article
- 2016
-
Mark
Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of lewy body diseases : Results from a large multicenter cohort
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
(
- Contribution to journal › Article
-
Mark
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.
2015) In Alzheimer's & Dementia(
- Contribution to journal › Article
-
Mark
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
(
- Contribution to journal › Article
- 2014
-
Mark
The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?
(
- Contribution to journal › Article
- 2012
-
Mark
Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
2012) In Neurology(
- Contribution to journal › Article
- 2009
-
Mark
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
(
- Contribution to journal › Article